Lowenstein Sandler represented Hildred Capital in the transaction. Hildred Capital raised $750 million for its continuation fund to extend its ownership of two of its portfolio companies, Hyland’s...
Hildred Capital’s $750 Million Continuation Fund
Crown Laboratories’ Acquisition of StriVectin
Lowenstein advised Hildred Capital Management and Crown Laboratories on the deal, while Gibson, Dunn & Crutcher advised StriVectin and L Catterton. Hildred Capital Management (Hildred) and...